Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Sonoma Pharmaceuticals, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Revenue
12.8
16.7
19
17.9
18.6
12.6
13.3
12.7
14.3
19.5
Cost of revenue
7.16
9.35
10.1
9.81
12.1
8.64
8.8
7.99
8.82
12.1
Gross profit
5.67
7.31
8.88
8.12
6.56
3.99
4.48
4.75
5.47
7.42
Research and development
1.58
1.58
1.52
1.34
0.56
0.13
0.21
1.87
1.81
2.27
Selling, general and administrative
17.1
19.9
18.6
14.2
9.45
9.76
8.84
7.58
7.36
7.61
Operating expenses
18.6
21.5
20.1
15.5
10
9.88
9.05
9.45
9.18
9.88
Operating income
-13
-14.2
-11.3
-7.39
-3.45
-5.89
-4.57
-4.7
-3.71
-2.46
Interest expense
0
0.04
0.03
0.02
0.01
Interest income
0.02
0.26
0.19
0.05
0.02
Pre-tax income
-12.9
-14.3
-11.3
-3.54
-3.9
-5.42
-5.18
-5.03
-2.91
-3.42
Income tax
-4.27
0.05
0.46
0.03
0.71
-0.33
-0.03
-0.2
0.55
-0.24
Income from continuing operations
-3.57
-4.62
Net income
9.27
-14.3
-11.8
-3.31
-3.95
-5.09
-5.15
-4.84
-3.46
-3.18
EBITDA
-12.7
-13.7
-10.8
-7.08
-3.22
-5.7
-4.45
-4.53
-3.57
-2.32
EPS, basic
447.80
-643.20
-288.30
-44.93
-39.51
-38.51
-30.49
-10.63
-2.79
-1.89
EPS, diluted
447.80
-643.20
-288.30
-44.93
-39.51
-38.51
-30.49
-10.63
-2.79
-1.89
Shares, basic (weighted)
0.02
0.02
0.04
0.07
0.1
0
0.17
0.46
1.24
1.68
Shares, diluted (weighted)
0.02
0.02
0.04
0.07
0.1
0
0.17
0.46
1.24
1.68
Balance sheet
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
17.5
10.1
3.69
3.69
4.22
7.4
3.82
3.13
5.37
2.4
Receivables
2.11
1.54
3.48
3.97
2.81
2.41
2.57
2.9
2.23
2.53
Inventory
2.22
2.87
3.41
2.18
2.53
2.66
2.86
2.72
2.92
3.65
Other current assets
0.62
1.55
1.69
2.26
3.22
3.75
4.31
3.54
1.92
3.52
Total current assets
22.6
16.3
12.5
12.3
13
16.4
13.8
12.5
12.6
12.1
Property, plant and equipment
1.24
1.14
0.73
0.37
0.36
0.32
0.49
0.37
0.23
0.31
Lease right-of-use assets
0
0.36
0.77
0.56
0.42
0.29
0.08
0.6
Other non-current assets
0.08
0.49
0.12
0.06
0.11
0.08
0.07
0.07
0.07
0.06
Total assets
25.5
19.2
14.4
14.6
15
18.8
16.2
14.7
13.7
14
Accounts payable
1.26
1.27
1.26
2.07
1.77
1.64
0.84
0.61
0.95
1.92
Accrued liabilities
0.68
0.82
0.96
1.08
0.79
1.06
1.46
1.42
1.74
1.72
Deferred revenue
0.35
0.15
0.05
0.23
0.27
1.22
0.16
0.48
0.64
0.28
Short-term debt
0.12
0.23
0.32
0.48
0.6
0.43
0.32
0.22
0.22
Total current liabilities
3.29
3.26
3.59
4.73
4.08
5.82
3.72
3.72
4.1
4.83
Long-term debt
0.05
0.03
0.01
0
1.31
0
Lease liabilities
0
0.24
0.53
0.31
0.16
0.09
0.03
0.47
Total liabilities
4.03
3.88
3.96
8.94
9.62
10.1
8.25
8.6
9.28
10.9
Total debt
0.17
0.26
0.33
0.48
1.91
0
Paid-in capital
169
177
184
187
189
197
201
203
207
207
Retained earnings
-143
-157
-169
-175
-179
-184
-190
-194
-198
-201
Other comprehensive income
-4.18
-3.98
-4.35
-5.61
-4.58
-4.31
-3.42
-2.72
-4.38
-3.24
Shareholders' equity
21.4
15.3
7.77
5.62
5.36
8.7
7.98
6.14
4.41
3.1
Total equity
21.4
15.3
7.77
5.62
5.36
8.7
7.98
6.14
4.41
3.1
Total liabilities and equity
25.5
19.2
14.4
14.6
15
18.8
16.2
14.7
13.7
14
Shares outstanding
0.02
0.03
0.06
0.09
0.1
0.15
0.25
0.78
1.63
1.8
Cash flow statement
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
9.27
-14.3
-11.8
-3.31
-3.52
-5.4
-5.18
-4.92
-2.91
-3.18
Depreciation and amortization
0.25
0.49
0.45
0.31
0.23
0.19
0.13
0.18
0.14
0.14
Stock-based compensation
2.15
2.5
1.64
0.84
0.37
0.38
0.67
0.52
0.22
0.26
Deferred income tax
-4.27
0.05
0.46
0.12
0.94
-0.33
-0.03
0.2
-0.55
0.24
Change in receivables
-0
0.01
-1.16
-2.19
2.61
1.97
-0
-0.23
0.43
-0.12
Change in inventory
-0.68
-0.58
-0.78
0.32
-0.07
-0.1
0
0.18
-0.39
-0.47
Change in payables
-0.06
0.01
0.01
0.34
Cash from operations
-8.17
-12.4
-11.7
-4.59
-3.38
-4.25
-6.15
-2.4
-0.09
-3.93
Capital expenditures
-0.39
-0.19
-0.1
-0.21
-0.18
-0.14
-0.27
-0
-0.08
-0.19
Sales and maturities of investments
0
Cash from investing
18.2
-0.2
-0.13
3.64
0.39
-0.1
-0.26
-0
-0.08
-0.19
Debt repaid
-0.13
-0.15
-0.15
-0.33
-0.48
-0.03
-0.77
Stock issued
0
0.97
0.96
1.38
0
7.55
2.87
1.78
3.08
0.43
Cash from financing
-0.03
5.24
5.49
1.03
3.31
7.4
2.49
1.68
3.03
0.48
Exchange rate effect
-0.03
0.01
-0.02
-0.08
0.21
0.13
0.35
0.03
-0.62
0.67
Net change in cash
9.99
-7.4
-6.38
0
0.53
3.18
-3.58
-0.69
2.25
-2.98
Free cash flow
-8.56
-12.6
-11.8
-4.8
-3.56
-4.39
-6.42
-2.4
-0.17
-4.13
Interest paid
0
0.04
0.03
0.02
0.01
0.02
0.02
0.02
0.01
0.01
Income taxes paid
0
0.94
0.77
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.27 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
38.9%
Gross profit / revenue.
Operating margin
-6.4%
Operating income / revenue.
Pre-tax margin
-11.4%
Pre-tax income / revenue.
Net margin
-10.3%
Net income / revenue.
FCF margin
-12.1%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-11.7%
Cash from operations / revenue.
Return on equity (ROE)
-34.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-12.5%
Net income / average total assets.
Return on invested capital (ROIC)
-88.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
10.4%
Research and development expense / revenue.
SG&A / revenue
34.9%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
1.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.4%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
36.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
13.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
0.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
35.7%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
18.3%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
2.5%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-29.8%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-27.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-10.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
1.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-4.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-1.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
35.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
115.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
76.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.99x
Current assets / current liabilities.
Quick ratio
1.56x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.98x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.59
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$5.70
Revenue / diluted weighted shares.
FCF per share
-$0.69
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.67
Cash from operations / diluted weighted shares.
Book value per share
$1.38
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.28x
Market cap / revenue.
P/B
0.92x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.92x
Market cap / tangible book value, when positive.
EV/Sales
0.03x
Enterprise value / revenue.
FCF yield
-43.7%
Free cash flow / market cap.
Earnings yield
-37.2%
Net income / market cap (the inverse of P/E).
What was Sonoma Pharmaceuticals, Inc.'s revenue in fiscal 2026?
Sonoma Pharmaceuticals, Inc. reported revenue of $19.5M for fiscal 2026, 36.7% higher than the year before.
Was Sonoma Pharmaceuticals, Inc. profitable in fiscal 2026?
No. It reported a net loss of $3.2M.
How much free cash flow did Sonoma Pharmaceuticals, Inc. generate in fiscal 2026?
Cash from operations of $3.9M minus capital expenditures of $192.0K left free cash flow of -$4.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.